97 related articles for article (PubMed ID: 26881634)
1. Primary cardiac lymphoblastic B-cell lymphoma: Should we treat more intensively?
Pires Ferreira Filho LI; Ribeiro Junior HL; Pinheiro Junior ED; Pinheiro RF
J Cancer Res Ther; 2015; 11(4):1034. PubMed ID: 26881634
[TBL] [Abstract][Full Text] [Related]
2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
3. Primary cardiac lymphoma: report of two cases occurring in immunocompetent subjects.
Anghel G; Zoli V; Petti N; Remotti D; Feccia M; Pino P; Majolino I
Leuk Lymphoma; 2004 Apr; 45(4):781-8. PubMed ID: 15160956
[TBL] [Abstract][Full Text] [Related]
4. Primary cardiac lymphoma: clinical, histologic, immunophenotypic, and genotypic features of 5 cases of a rare disorder.
Nascimento AF; Winters GL; Pinkus GS
Am J Surg Pathol; 2007 Sep; 31(9):1344-50. PubMed ID: 17721189
[TBL] [Abstract][Full Text] [Related]
5. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma.
Coso D; Sebban C; Boulat O; Biron P; Rey J; Aurran T; Chabannon C; Xerri L; Chetaille B; Esterni B; Ivanov V; Stoppa AM; Schiano de Collela JM; Gastaut JA; Maraninchi D; Bouabdallah R
Bone Marrow Transplant; 2006 Aug; 38(3):217-22. PubMed ID: 16770316
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of primary mediastinal large B-cell lymphomas].
Schneider T; Tóth E; Molnár Z; Várady E; Deák B; Horváth A; Horváth GI; Eid H; Schneider K; Lovey J; Keresztes S; Esik O; Lengyel Z; Rosta A
Orv Hetil; 2004 Dec; 145(50):2531-7. PubMed ID: 15662753
[TBL] [Abstract][Full Text] [Related]
9. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
Thomas DA; Faderl S; O'Brien S; Bueso-Ramos C; Cortes J; Garcia-Manero G; Giles FJ; Verstovsek S; Wierda WG; Pierce SA; Shan J; Brandt M; Hagemeister FB; Keating MJ; Cabanillas F; Kantarjian H
Cancer; 2006 Apr; 106(7):1569-80. PubMed ID: 16502413
[TBL] [Abstract][Full Text] [Related]
10. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
11. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
Pardal E; Coronado M; Martín A; Grande C; Marín-Niebla A; Panizo C; Bello JL; Conde E; Hernández MT; Arranz R; Bargay J; González-Barca E; Pérez-Ceballos E; Montes-Moreno S; Caballero MD
Br J Haematol; 2014 Nov; 167(3):327-36. PubMed ID: 25066542
[TBL] [Abstract][Full Text] [Related]
12. Complete remission in two cases of adult T-cell leukemia/lymphoma treated with hyper-CVAD: a case report and review of the literature.
Alduaij A; Butera JN; Treaba D; Castillo J
Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):480-3. PubMed ID: 21156467
[TBL] [Abstract][Full Text] [Related]
13. [Primary cardiac lymphoma: cytological diagnosis and treatment with response to polychemotherapy and hematopoietic precursor autotransplant. Presentation of a case a review of the literature].
Porcar Ramells C; Clemente González C; García Parés D; Guardia Sánchez R; Pérez Ayuso MJ; García-Bragado Dalmau F
An Med Interna; 2002 Jun; 19(6):305-9. PubMed ID: 12152391
[TBL] [Abstract][Full Text] [Related]
14. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
15. Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies.
Friedberg JW; Neuberg D; Gribben JG; Mauch P; Anderson KC; Soiffer RJ; Takvorian T; Fisher DC; Schlossman R; Jallow H; Kuhlman C; Ritz J; Freedman AS
Biol Blood Marrow Transplant; 1999; 5(4):262-8. PubMed ID: 10465106
[TBL] [Abstract][Full Text] [Related]
16. Autologous peripheral blood progenitor cell transplantation for non-Hodgkin's lymphoma with extensive bone marrow necrosis.
Khan AM; Yamase H; Tutschka PJ; Bilgrami S
Bone Marrow Transplant; 1997 May; 19(10):1037-9. PubMed ID: 9169650
[TBL] [Abstract][Full Text] [Related]
17. [A case of primary malignant lymphoma of the pararectal space].
Tanaka M; Matsuzaki J; Kitami K; Hirokawa M
Hinyokika Kiyo; 2002 Sep; 48(9):561-4. PubMed ID: 12402484
[TBL] [Abstract][Full Text] [Related]
18. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma.
Verdonck LF; van Putten WL; Hagenbeek A; Schouten HC; Sonneveld P; van Imhoff GW; Kluin-Nelemans HC; Raemaekers JM; van Oers RH; Haak HL
N Engl J Med; 1995 Apr; 332(16):1045-51. PubMed ID: 7898521
[TBL] [Abstract][Full Text] [Related]
19. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Philip T; Guglielmi C; Hagenbeek A; Somers R; Van der Lelie H; Bron D; Sonneveld P; Gisselbrecht C; Cahn JY; Harousseau JL
N Engl J Med; 1995 Dec; 333(23):1540-5. PubMed ID: 7477169
[TBL] [Abstract][Full Text] [Related]
20. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]